Kalevalatherapeutics focuses on repurposing existing drugs to create accessible treatments for patients with rare diseases, addressing the fact that 95% of such conditions lack approved therapies. The company prioritizes indications with credible evidence, collaborates with clinicians, partners, and patient advocates, and maps tailored regulatory pathways to accelerate approval. By leveraging known safety profiles, they aim to deliver faster, cost‑effective therapeutic options for urgent, unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Most rare diseases—about 95%—have no approved therapies, leaving patients without effective treatment options and clinicians with limited options for care.
Solution
Kalevalatherapeutics focuses on drug repurposing to create new therapeutic uses for existing, approved medicines. By systematically identifying rare disease indications where existing clinical data provide credible evidence, the company shortens development timelines and reduces risk. It collaborates with clinicians, patient advocates, and industry partners to define regulatory strategies, secure designations, and advance filings. The approach aims to deliver accessible, patient‑focused treatments for urgent, unmet medical needs across several focus areas, including lysosomal storage disorders, neurovascular diseases, CNS histiocytosis, and channelopathies.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to expand their pipelines through repurposed assets, as well as patient advocacy groups and clinicians focused on rare disease treatment development.
Features
- Systematic identification of repurposing opportunities using in‑silico analysis and existing safety data
- Prioritization framework that selects rare disease targets with strong mechanistic rationale and clinical evidence
- Collaborative model engaging clinicians, advocates, and pharmaceutical partners to shape development plans
- Regulatory pathway mapping that leverages existing designations (e.g., FDA Orphan Drug Designation) to accelerate approvals
- Portfolio spanning multiple disease categories, with candidates progressing from preclinical to IND‑enabling and clinical stages